Population-based study finds patients who use thiazide medications face a nearly fivefold increased risk of developing hyponatremia compared to patients who do not use these medications.
Both corrected and persistent hyponatremia are predictors of all-cause mortality in patients presenting with myocardial infarction.
Results from a small retrospective study indicate that treatment with tolvaptan increases sodium concentrations and excretion rhythm without significantly affecting kidney function in patients with refractory hyponatremia and dcompensated heart failure.
Citing an increased risk of liver injury observed in recent clinical trials, the US Food and Drug Administration (FDA) has limited Samsca (tolvaptan) treatment to 30 days and recommended the oral selective vasopressin V2-receptor antagonist be discontinued in patients with signs of liver disease or symptoms of liver injury.
Approved by the FDA nearly four years ago, Otsuka Group’s once-daily Samsca (tolvaptan tablets) is indicated to raise serum sodium levels in nonurgent patients with hyponatremia.